Search results
Showing 136 to 150 of 171 results for leukaemia
Discontinued Reference number: GID-TA10133
Next-generation sequencing panel for solid tumour cancers in children (MIB133)
NICE has developed a medtech innovation briefing (MIB) on the next-generation sequencing panel for solid tumour cancers in children .
This guidance has been updated and replaced by NICE technology appraisal guidance 70 [Partially updated by NICE technology appraisal guidance 241].
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.
Venetoclax for treating chronic lymphocytic leukaemia (TA487)
This guidance has been updated and replaced by NICE technology appraisal guidance 796.
Bosutinib for previously treated chronic myeloid leukaemia (TA299)
This guidance has been updated and replaced by NICE technology appraisal guidance 401.
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)
This guidance has been updated and replaced by NICE technology appraisal guidance 1119.
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued Reference number: GID-HST10038
This advice has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.
Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.
This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.